XTRA Fundamental Analysis - XTRACT ONE TECHNOLOGIES INC

Fundamental Rating

XTRA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 11 industry peers in the Aerospace & Defense industry. XTRA may be in some trouble as it scores bad on both profitability and health. XTRA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

XTRA had negative earnings in the past year.

In the past year XTRA has reported a negative cash flow from operations.

In the past 5 years XTRA always reported negative net income.

In the past 5 years XTRA always reported negative operating cash flow.

1.2 Ratios

XTRA's Return On Assets of -50.37% is on the low side compared to the rest of the industry. XTRA is outperformed by 72.73% of its industry peers.

XTRA has a Return On Equity of -115.48%. This is in the better half of the industry: XTRA outperforms 72.73% of its industry peers.

		Industry Rank	Sector Rank
ROA	-50.37%
ROE	-115.48%
ROIC	N/A

ROA(3y)-60.36%

ROA(5y)-86.91%

ROE(3y)-100.39%

ROE(5y)-121.9%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 63.66%, XTRA belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for XTRA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.

XTRA has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, XTRA has more shares outstanding

XTRA has a worse debt/assets ratio than last year.

2.2 Solvency

XTRA has an Altman-Z score of -2.64. This is a bad value and indicates that XTRA is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of XTRA (-2.64) is worse than 72.73% of its industry peers.

A Debt/Equity ratio of 0.08 indicates that XTRA is not too dependend on debt financing.

With an excellent Debt to Equity ratio value of 0.08, XTRA belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-2.64

ROIC/WACCN/A

WACC9.01%

2.3 Liquidity

A Current Ratio of 1.71 indicates that XTRA should not have too much problems paying its short term obligations.

The Current ratio of XTRA (1.71) is better than 81.82% of its industry peers.

A Quick Ratio of 1.35 indicates that XTRA should not have too much problems paying its short term obligations.

With an excellent Quick ratio value of 1.35, XTRA belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.71
Quick Ratio	1.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.49% over the past year.

The Revenue for XTRA has decreased by -12.14% in the past year. This is quite bad

Measured over the past years, XTRA shows a very strong growth in Revenue. The Revenue has been growing by 46.26% on average per year.

EPS 1Y (TTM)3.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

Revenue 1Y (TTM)-12.14%

Revenue growth 3Y56.42%

Revenue growth 5Y46.26%

Sales Q2Q%26.69%

3.2 Future

XTRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.

Based on estimates for the next years, XTRA will show a very strong growth in Revenue. The Revenue will grow by 62.98% on average per year.

EPS Next Y49%

EPS Next 2Y41.42%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year79.71%

Revenue Next 2Y62.98%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XTRA. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XTRA's earnings are expected to grow with 41.42% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.42%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XTRA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

XTRACT ONE TECHNOLOGIES INC

TSX:XTRA (12/18/2025, 7:00:00 PM)

0.65

+0.05 (+8.33%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryAerospace & Defense

Earnings (Last)12-03 2025-12-03/amc

Earnings (Next)03-10 2026-03-10

Inst Owners0.38%

Inst Owner ChangeN/A

Ins Owners0.44%

Ins Owner ChangeN/A

Market Cap168.23M

Revenue(TTM)14.82M

Net Income(TTM)-11.94M

Analysts82.5

Price Target1.1 (69.23%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)1.96%

Min EPS beat(2)1.96%

Max EPS beat(2)1.96%

EPS beat(4)3

Avg EPS beat(4)-10.29%

Min EPS beat(4)-96.08%

Max EPS beat(4)50.98%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-14.37%

Min Revenue beat(2)-26.53%

Max Revenue beat(2)-2.21%

Revenue beat(4)0

Avg Revenue beat(4)-16.37%

Min Revenue beat(4)-34.03%

Max Revenue beat(4)-2.21%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)7.5%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-66.67%

Revenue NQ rev (1m)-6.66%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-10.08%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	11.35
P/FCF	N/A
P/OCF	N/A
P/B	16.27
P/tB	27.96
EV/EBITDA	N/A

EPS(TTM)-0.05

EYN/A

EPS(NY)0

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.02

OCFYN/A

SpS0.06

BVpS0.04

TBVpS0.02

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-50.37%
ROE	-115.48%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.66%
FCFM	N/A

ROA(3y)-60.36%

ROA(5y)-86.91%

ROE(3y)-100.39%

ROE(5y)-121.9%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.63

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	19.64%
Cap/Sales	3.16%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.71
Quick Ratio	1.35
Altman-Z	-2.64

F-Score3

WACC9.01%

ROIC/WACCN/A

Cap/Depr(3y)20.53%

Cap/Depr(5y)19.86%

Cap/Sales(3y)3.35%

Cap/Sales(5y)13.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)3.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%0%

EPS Next Y49%

EPS Next 2Y41.42%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-12.14%

Revenue growth 3Y56.42%

Revenue growth 5Y46.26%

Sales Q2Q%26.69%

Revenue Next Year79.71%

Revenue Next 2Y62.98%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-3.14%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year81.47%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y50.59%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y54.31%

OCF growth 3YN/A

OCF growth 5YN/A

XTRACT ONE TECHNOLOGIES INC / XTRA.CA FAQ

What is the fundamental rating for XTRA stock?

ChartMill assigns a fundamental rating of 3 / 10 to XTRA.CA.

What is the valuation status for XTRA stock?

ChartMill assigns a valuation rating of 1 / 10 to XTRACT ONE TECHNOLOGIES INC (XTRA.CA). This can be considered as Overvalued.

How profitable is XTRACT ONE TECHNOLOGIES INC (XTRA.CA) stock?

XTRACT ONE TECHNOLOGIES INC (XTRA.CA) has a profitability rating of 1 / 10.

What is the financial health of XTRACT ONE TECHNOLOGIES INC (XTRA.CA) stock?

The financial health rating of XTRACT ONE TECHNOLOGIES INC (XTRA.CA) is 3 / 10.

XTRACT ONE TECHNOLOGIES INC (XTRA.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

XTRACT ONE TECHNOLOGIES INC / XTRA.CA FAQ

What is the fundamental rating for XTRA stock?

What is the valuation status for XTRA stock?

How profitable is XTRACT ONE TECHNOLOGIES INC (XTRA.CA) stock?

What is the financial health of XTRACT ONE TECHNOLOGIES INC (XTRA.CA) stock?